Clinical Trial Update: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial evaluating ipilimumab monotherapy in patients with previously treated unresectable stage III or IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED